LENSAR

LENSAR P/FCF

The P/FCF (Price-to-Free-Cash-Flow Ratio) of LENSAR (LNSR) as of Oct 20, 2026 is -9.79. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was -60.09 — a change of -83.70% (higher).

P/FCF

-9.79

YoY

-83.70%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of LENSAR is 2025 -9.79 . P/FCF (Price-to-Free-Cash-Flow Ratio) of LENSAR was 2024 -60.09 . It decreases by -83.70% higher compared to the previous year.

The LENSAR P/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/FCF
Date
P/FCF
Jan 1, 2018
-28.46 USD
Jan 1, 2019
-9.95 USD
Jan 1, 2020
-10.32 USD
Jan 1, 2021
-15.67 USD
Jan 1, 2022
-9.76 USD
Jan 1, 2023
-14.76 USD
Jan 1, 2024
-60.09 USD
Jan 1, 2025
-9.79 USD
The LENSAR P/FCF history
YEARP/FCFYoY
-9.79-83.70%
-60.09+307.03%
-14.76+51.30%
-9.76-37.73%
-15.67+51.85%
-10.32+3.68%
-9.95-65.03%
-28.46—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

LENSAR Stock analysis

What does LENSAR do? LENSAR, Inc. generates revenue through the sale of its femtosecond laser systems, specifically the LENSAR Laser System with Streamline IV and IntelliAxis, and the ALLY Adaptive Cataract Treatment System. The LENSAR Laser System includes disposable patient interface device kits as consumables, which contribute to recurring revenue. Surgeons and ophthalmic clinics purchasing these systems form the primary customer segment, utilizing the technology for cataract surgery and corneal astigmatism management. The company's focus on proprietary technologies ensures differentiation in the medical device market. The ALLY System is marketed as a compact solution for femtosecond laser assisted cataract procedures, designed to streamline surgical workflows within a single operating room. Its product portfolio emphasizes integrated features that enhance visual outcomes for patients. The consumable components, such as the disposable patient interface device kits, support ongoing revenue streams alongside the initial system sales. These offerings target healthcare providers seeking advanced surgical tools for refractive cataract surgery. LENSAR's business model relies on selling high-precision medical devices to specialized healthcare facilities. The LENSAR Laser System and ALLY System are positioned as premium solutions for cataract treatment, with the consumables providing sustained revenue opportunities. The company's product development centers around improving surgical efficiency and patient visual results through its patented technologies. LENSAR is one of the most popular companies on Eulerpool.

Frequently Asked Questions about LENSAR stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of LENSAR is -9.79 in 2025.

P/FCF (Price-to-Free-Cash-Flow Ratio) of LENSAR changed from -60.09 to -9.79, representing a -83.70% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) LENSAR since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s LENSAR with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — LENSAR

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — LENSAR